Presentation

Poster

  • Progressive Loss of EGFR in a subpoulation of breast cancers: Implications in target-directed therapeutics. Lee Yee Choong, Simin Lim, Marie Chiew-Shia Loh, Xiaohui Man, Yunhao Chenm Weiyi Toy, Mengfei Pan, Chien-Shing Chen, Anuradha Poonepalli, MPrakash, Hande, Puay Hoon Tan,, Manual Salto-Tellez, Chow-Yin Wong, Nilesh Shah, Brian J Druker, Yoon-Pin Lim. Translational Cancer Medicine, AACR Centennial Conference 2007 Nov 4-8: Poster Session B (B33) (09/2007 - 09/2009)
  • Soh TG, Ho R, Che GL, Chen CS and Tan LK. Large Scale CD8+ T-Cell Depletion Using Magnetic Cell Sorting Technique for a Pilot Trial Study on Pre-emptive CD8+ T-cell Depleted Donor Lymphocyte Infusion Following Nonmyeloablative Stem Cell Transplantation for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome. poster presentation at 2007 AABB Annual Conference, October 20 - 23, Anaheim, California. (09/2007 - 09/2008)
  • Phase I and biomarker study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. C-I Wong, C-H Thng, N Sukri, R Soo, R Carr, E McKeegan, S-C Lee, CS Chen, R Humerickhouse, B-C Goh. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 25, No 18S (June 20 Supplement), 2007: 3519. 2007. (09/2007 - 09/2008)
  • Overactivation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. J. Zhou, Bi C, Poon LF, Janakakumara VJ, Khng J, Yu H, K. Glaser, D. Albert, S. Davidsen, CS Chen. Blood 118 (11): 699a, Nov 16, 2007. (09/2007 - 09/2008)
  • SB939: A Potent, and orally-active HDAC inhibitor for the treatment of haematologic malignancies. Sangthongpitag K, Stunkel W, Bonday Z, Goh KC, Wang X, Wu X, Hu C, Eric Sun, Wang H, Yu N, Entzeroth M, Ethirajulu K, Chen CS, Wood J. Blood, 118 (11): 479a, Nov 16, 2007. (09/2007 - 09/2008)
  • ABT-869, a multiple tyrosine kinase inhibitor, has promising activity in patients with non-small cell lung cancer (NSCLC) in a phase I dose escalation study. Soo R, Thng CH, Sukri N, Wong C-I, Lee SC, Chen CS, Humerickhouse, R, Goh BC. Journal of Thoracic Oncology, 2(8) Supplement 4August 2007 pp S458-S459. (09/2007 - 09/2008)
  • A Potent, orally-active HDAC inhibitor for the treatment of haematologic malignancies and solid tumors. Translational Cancer Medicine, Sangthongpitag K, Wang H, Stunkel W, Bonday Z, Goh KC, Wang X, Wu XF, Hu CY, Sun E, Entzeroth M, Reddy V, Goh E, Yeo P, Chen CS, Greicius G, Pettersson S, Ethirajulu K, Wood J.   AACR Centennial Conference 2007 Nov 4-8 Singapore: Poster Session C14. (09/2007 - 09/2008)
  • Development Of P53 Antisense Oligonucleotide Repository: To Knock Down P53 Oncogenic Mutations For Personalized Cancer Therapy Zhigang Xie, Kian Ghee Tay, Shaw Cheng Liu, Jianbiao Zhou, Wee Joo Chng, C-S Chen. presented 4th Annual Meeting of the Oligonucleotide Therapeutics Society, Boston, MA, October 15-18, 2008 (09/2008 - 09/2009)
  • Bortezomib therapy for prostate specific antigen (PSA)-only relapse after definitive local therapy. J. S. Turner, C. S. Chen, W. Butler, J. Bearden III, E. Garrett-Mayer, G. Onicescu, A. S. Kraft. J Clin Oncol 27: 2009 (suppl; abstr e16053) (09/2009 - 09/2010)
  • The effect of varying doses of ABT-869 on biomarkers of angiogenesis and their correlation with pharmacodynamic outcome. R. A. Soo, E. McKeegan, C. S. Chen, C. H. Thng, T. S. Koh, D. Laird, K. Zhang, C. I. Wong, N. Gupta, B. C. Goh. J Clin Oncol 26: 2008 (May 20 suppl; abstr 14535) (09/2009 - 09/2010)

Research

  • Anti-cancer activity of liposomal safingol for leukemia. LING Leong Uung, LIM Rou Wei, CHU Pat Pak Yan, CHEN Chien Shing, CHIU Gigi Ngar Chee. The 32nd World Congress of the International Society of Hematology, Oct 19-23, 2008, Bangkok Convention Center at Central World, Bangkok, Thailand (09/2008 - 09/2009)
  • Association between YM155 resistance and extracellular survivin splice variants in acute myeloid leukemia. CS Chen, Rosalia de Necochea-Campion, Saied Mirshahidi, Nathan R. Wall. Presented at ISEV 2014 (International Society for Extracellular Vesicles), Rotterdam, The Netherlands, April 30 - May 3, 2014; poster ABSSUB#278 (04/2014 - 05/2014)
  • High Transcription Levels Of S100A8 and S100A9 In Acute Myeloid Leukemia Are Predictors For Poor Overall Survival. Shao-yan Hu, Ming-ying Zhang, Shui-yan Wu, Dong Wu, Neetika Ashwani, Jian Pan, Hai-long He, Jian-nong Cen, Zi-Xing Chen, and Chien-Shing Chen.Blood(ASH Annual Meeting Abstracts), Nov 2013; poster #3610. (11/2013)
  • BCL2 family pro-death and pro-survival proteins in Ph-like B cell precursor acute lymphoblastic leukemia. Kamal MO, Stoian C, Aponte-Paris S, Reed M, Choi H, Coats J, Chirshev E, Chen CS, Payne KJ. Presented at poster presentation #7030. J Clin Oncol 34, 2016 (suppl; abstr 7030), ASCO 2016 (06/2016)